| [1] |
Cook AM, Hatton-Kolpek J. Augmented Renal Clearance[J]. Pharmacotherapy，2019，39(3)：346-354.
|
| [2] |
Loirat P, Rohan J, Baillet A，et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin[J]．The New England Journal of Medicine, 1978，299(17)：915-919.
|
| [3] |
Carlier M, De Waele JJ. Identifying patients at risk for augmented renal clearance in the ICU - limitations and challenges[J]. Crit Care，2013，17(2)：130.
|
| [4] |
De Waele JJ, Dumoulin A, Janssen A，et al. Epidemiology of augmented renal clearance in mixed ICU patients[J]. Minerva Anestesiol，2015，81(10)：1079-1085.
|
| [5] |
Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients[J]. Clinical Pharmacology and Therapeutics, 1988，44(1)：9-13.
|
| [6] |
Morbitzer KA, Jordan JD, Rhoney DH. Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion[J]. Neurocrit Care, 2015，22(2)：258-264.
|
| [7] |
Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented renal clearance in critically ill patients: a systematic review[J]. Clin Pharmacokinet，2018，57(9)：1107-1121.
|
| [8] |
Udy AA, Roberts JA, Shorr AF，et al. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk patients[J]. Crit Care，2013，17：R35.
|
| [9] |
Barletta JF, Mangram AJ, Byrne M，et al. Identifying augmented renal clearance in trauma patients: validation of the augmented renal clearance in trauma intensive care (arctic) scoring system[J]. J Trauma Acute Care Surg, 2017，82(4)：665-671.
|
| [10] |
Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations[J]. Crit Care Med, 2014, 42(3): 520-527.
|
| [11] |
杨柳，角述兰，思永玉，等．不同烧伤程度患者靶控输注丙泊酚的药代动力学[J]．临床麻醉学杂志，2018，34(8)：777-781.
|
| [12] |
Huttner A, Von Dach E, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study[J]. International Journal of Antimicrobial Agents, 2015，45(4)：385-392.
|
| [13] |
Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance？[J]. Crit Care，2015，19(1)：28.
|
| [14] |
Selig DJ, Akers KS, Chung KK, et al. Comparison of piperacillin and tazobactam pharmacokinetics in critically ill patients with trauma or with burn[J]. Antibiotics (Basel), 2022，11(5)：618.
|
| [15] |
Torian SC, Wiktor AJ, Roper SE, et al. Burn injury and augmented renal clearance: a case for optimized piperacillin-tazobactam dosing[J]. J Burn Care Res，2023，44(1)：203-206.
|
| [16] |
Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J]. Int J Clin Pharmacol Ther，2007，45(3)：133-142.
|
| [17] |
Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns[J]. Clin Pharmacol Ther，1990，48(2)：130-137.
|
| [18] |
Selig DJ, Akers KS, Chung KK, et al. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration[J]. Br J Clin Pharmacol，2022，88(5)：2156-2168.
|
| [19] |
Bakke V, Sporsem H, Von der Lippe E, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study[J]. Acta Anaesthesiol Scand, 2017，61(6)：627-635.
|
| [20] |
Conil JM, Favarel H, Laguerre J, et al. Continuous administration of vancomycin in patients with severe burns[J]. Presse Med，1994，23(34)：1554-1558.
|
| [21] |
Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper[J]. Intensive Care Med，2020，46(6)：1127-1153.
|
| [22] |
Hu S, Wang T, You H, et al. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance[J]. J Clin Pharm Ther，2022，47(10)：1548-1555.
|
| [23] |
Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients[J]. J Antimicrob Chemother，1996，37(3)：545-553.
|
| [24] |
Carrié C, Delzor F, Roure S, et al. Population pharmacokinetic study of the suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy[J]. Antimicrob Agents Chemother，2020，64(4)：e02098-02119.
|
| [25] |
Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients[J]. The Journal of Trauma, 1976，16(10)：824-828.
|
| [26] |
Borra LC, Bosch TM, van Baar ME, et al. Adequacy of a hospital-wide standard dose of 7mg/kg bodyweight gentamicin sufficient to achieve an adequate prophylactic maximum serum concentration (cmax) in burn patients undergoing surgical burn wound treatment[J]. Burns, 2016，42(8)：1819-1824.
|
| [27] |
Bracco D, Landry C, Dubois MJ, et al. Pharmacokinetic variability of extended interval tobramycin in burn patients[J]. Burns，2008，34(6)：791-796.
|
| [28] |
Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries[J]. J Burn Care Rehabil. 1997，18(2)：116-124.
|
| [29] |
Roberts JA, Cotta MO, Cojutti P, et al. Does critical illness change levofloxacin pharmacokinetics？[J]. Antimicrob Agents Chemother，2015，60(3)：1459-1463.
|
| [30] |
Kiser TH, Hoody DW, Obritsch MD, et al. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury[J]. Antimicrob Agents Chemother，2006，50(6)：1937-1945.
|
| [31] |
Lesne-Hulin A, Bourget P, Ravat F, et al. Clinical pharmacokinetics of ciprofloxacin in patients with major burns[J]. Eur J Clin Pharmacol，1999，55(7)：515-519.
|
| [32] |
Van Daele R, Wauters J, Lagrou K, et al. Pharmacokinetic variability and target attainment of fluconazole in critically ill patients[J]. Microorganisms，2021，9(10)：2068.
|
| [33] |
Han S, Kim J, Yim H, et al. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with candida infection[J]. Antimicrob Agents Chemother, 2013，57(2)：1006-1011.
|
| [34] |
Akers KS, Rowan MP, Niece KL, et al. Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report[J]. BMC Infect Dis，2015，15：184.
|
| [35] |
Asensio MJ, Sánchez M, Galván B, et al. Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries[J]. Intensive Care Med，2015，41(2)：371-372.
|
| [36] |
Trupkovic T, Kinn M, Kleinschmidt S. Analgesia and sedation in the intensive care of burn patients: results of a European survey[J]. Journal of Intensive Care Medicine, 2011，26(6)：397-407.
|
| [37] |
Bae JY, Choi DY, Woo CH, et al. The BIS and hemodynamic changes in major burn patients according to a slow infusion of propofol for induction[J]. Korean Journal of Anesthesiology, 2011，60(3)：161-166.
|
| [38] |
Martyn J, Greenblatt DJ. Lorazepam conjugation is unimpaired in burn trauma[J]. Clin Pharmacol Ther，1988，43(3)：250-255.
|
| [39] |
Perreault S, Choinière M, du Souich PB, et al. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries[J]. The Annals of Pharmacotherapy, 2001，35(12)：1588-1592.
|
| [40] |
Herman RA, Veng-Pedersen P, Miotto J, et al. Pharmacokinetics of morphine sulfate in patients with burns[J]. The Journal of Burn Care & Rehabilitation，1994，15(2)：95-103.
|
| [41] |
Dwersteg JF, Pavlin EG, Heimbach DM. Patients with burns are resistant to atracurium[J]. Anesthesiology, 1986，65(5)：517-520.
|
| [42] |
Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus[J]. British Journal of Anaesthesia, 2009，102(1)：55-60.
|
| [43] |
Martyn JA, Chang Y, Goudsouzian NG, et al. Pharmacodynamics of mivacurium chloride in 13- to 18-yr-old adolescents with thermal injury[J]．British Journal of Anaesthesia, 2002，89(4)：580-585.
|
| [44] |
Cato LD, Bailiff B, Price J, et al. Heparin resistance in severe thermal injury: a prospective cohort study[J]. Burns Trauma. 2021，9：tkab032.
|
| [45] |
Lu P, Harms KA, Paul E, et al. Venous thromboembolism in burns patients: are we underestimating the risk and underdosing our prophylaxis？[J]. J Plast Reconstr Aesthet Surg, 2021，74(8)：1814-1823.
|
| [46] |
Lin H, Faraklas I, Saffle J, et al. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients[J]. J Trauma, 2011，71(6)：1557-1561.
|
| [47] |
Bilbao-Meseguer I, Barrasa H, Asín-Prieto E, et al. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function[J]. Pharmaceutics, 2021，13(10)：1690.
|
| [48] |
Sime FB, Roberts JA, Jeffree RL, et al. Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance[J]. Clin Pharmacokinet，2021，60(5)：655-664.
|